Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.
LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Several new studies presented at the European
Lung Cancer Conference (ELCC) 2016 have confirmed the benefit of plasma circulating tumour DNA (ctDNA) testing for EGFR mutation analysis to predict treatment benefit of targeted therapies for non-small-cell lung cancer (NSCLC). Tissue biopsy, the gold standard for tumour genotyping, is not feasible in about 20 percent of patients, and plasma biomarkers are a potential alternative.
The development of immunotherapy and recent approval of agents which block various components of the immune checkpoint pathway, such as programmed cell death-1 (PD-1) receptor and its ligand PD-L1, have revolutionized lung cancer treatment.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.